LGND Ligand Pharmaceuticals Incorporated

117.93
+1.4  (+1%)
Previous Close 116.53
Open 116.51
Price To Book 2.14
Market Cap 2,311,183,066
Shares 19,598,405
Volume 21,041
Short Ratio
Av. Daily Volume 340,119

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA approval announced June 11, 2018.
KYPROLIS (ASPIRE)
Relapsed Multiple Myeloma
Phase 2a data released March 2, 2018.
RPL554
Cystic fibrosis
FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
FDA approval announced October 1, 2018.
KYPROLIS (ARROW)
Multiple Myeloma
sNDA approved January 17, 2018.
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
Data due by the end of 3Q 2019.
Ganaxolone
Refractory status epilepticus (RSE)
Data due first half of 3Q 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 top-line data due 2H 2020.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Phase 2b trial to be initiated 2H 2019.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
VK5211
Acute Hip Fracture
Phase 3 top-line data due mid-2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Data due first half of 3Q 2019.
Ganaxolone - oral (Amaryllis)
Postpartum depression
PDUFA date under priority review - October 24, 2019.
Baxdela
Community-acquired bacterial pneumonia (CABP)
Phase 3 data due 1H 2022.
Sparsentan
IgA nephropathy
Phase 2 data due 3Q 2019.
RPL554 DPI formulation
Maintenance treatment of COPD
Phase 3 data due 2019.
KYPROLIS (CANDOR)
Multiple Myeloma
Phase 1 top-line data met primary endpoint - July 10, 2019.
Captisol-enabled (CE) Iohexol program
Contrast-induced Nephropathy

Latest News

  1. Ligand to Report Second Quarter 2019 Results on July 30th
  2. Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expensive For A Reason? A Look At Its Intrinsic Value
  3. Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
  4. See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.
  5. Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
  6. ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics
  7. What does Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Balance Sheet Tell Us About Its Future?
  8. Ligand Inks Oncology Drug Discovery Deal With PhoreMost
  9. Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
  10. Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?
  11. Should You Worry About Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Salary Level?
  12. Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares
  13. Ligand Grants Preclinical Candidate Rights to UK-based Firm
  14. Ligand Licenses VER250840 to Cumulus Oncology
  15. A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE
  16. AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates